Your browser doesn't support javascript.
loading
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
Criscione, Steven W; Martin, Matthew J; Oien, Derek B; Gorthi, Aparna; Miragaia, Ricardo J; Zhang, Jingwen; Chen, Huawei; Karl, Daniel L; Mendler, Kerrin; Markovets, Aleksandra; Gagrica, Sladjana; Delpuech, Oona; Dry, Jonathan R; Grondine, Michael; Hattersley, Maureen M; Urosevic, Jelena; Floc'h, Nicolas; Drew, Lisa; Yao, Yi; Smith, Paul D.
Afiliación
  • Criscione SW; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA. Steven.Criscione@astrazeneca.com.
  • Martin MJ; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Oien DB; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Gorthi A; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Miragaia RJ; Department of Cell Systems & Anatomy, Greehey Children's Cancer Research Institute, University of Texas at Health San Antonio, San Antonio, TX, USA.
  • Zhang J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Chen H; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Karl DL; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Mendler K; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Markovets A; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Gagrica S; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Delpuech O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Dry JR; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Grondine M; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Hattersley MM; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Urosevic J; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Floc'h N; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Drew L; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Yao Y; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Smith PD; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA. yiyao1147@gmail.com.
NPJ Precis Oncol ; 6(1): 95, 2022 Dec 27.
Article en En | MEDLINE | ID: mdl-36575215
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos